Measuring Opioid Peptides in Human Blood: Dynorphin B Is Stable but Dynorphin A Rapidly Degrades
Dynorphin B and beta-endorphin circulate in human blood at measurable levels, but dynorphin A is rapidly converted to leu-enkephalin, explaining why it's undetectable in plasma.
Quick Facts
What This Study Found
Dynorphin B and beta-endorphin were confirmed in human plasma by HPLC and mass spectrometry, while dynorphin A was undetectable due to rapid enzymatic conversion to leu-enkephalin in blood.
Key Numbers
How They Did This
In-vitro analytical study using radioimmunoassay, HPLC, and mass spectrometry to characterize opioid peptides in human plasma. Stability experiments tracked dynorphin A degradation in blood.
Why This Research Matters
Understanding which opioid peptides are stable enough to circulate in blood versus those degraded immediately helps researchers choose the right biomarkers and design more stable peptide therapeutics.
The Bigger Picture
The body's opioid system includes many peptides with different stabilities and functions. Knowing that dynorphin A is rapidly degraded in blood while dynorphin B persists suggests they have fundamentally different roles — dynorphin A as a local signal, dynorphin B as a circulating one.
What This Study Doesn't Tell Us
In-vitro characterization study. Blood processing can affect peptide levels. Individual variation in peptide levels was not extensively characterized.
Questions This Raises
- ?What enzymes degrade dynorphin A so rapidly in blood?
- ?Could dynorphin B blood levels serve as a biomarker for pain or stress conditions?
- ?Can dynorphin A analogs be designed to resist blood degradation?
Trust & Context
- Key Stat:
- Rapid degradation Dynorphin A added to human plasma was rapidly converted to leu-enkephalin, explaining why it is undetectable in blood samples
- Evidence Grade:
- Preliminary evidence from a well-designed analytical study with mass spectrometric confirmation, providing reliable characterization data.
- Study Age:
- Published in 1998. These findings have informed subsequent research on opioid peptide stability and biomarker development.
- Original Title:
- Characterization of immunoreactive dynorphin B and beta-endorphin in human plasma.
- Published In:
- Peptides, 19(8), 1329-37 (1998)
- Authors:
- Silberring, J(6), Li, Y M, Terenius, L(6), Nylander, I
- Database ID:
- RPEP-00494
Evidence Hierarchy
Frequently Asked Questions
What are dynorphins?
Dynorphins are a family of opioid peptides produced naturally in the brain and body. They primarily activate kappa-opioid receptors and are involved in pain modulation, stress responses, and mood regulation.
Why does it matter that dynorphin A degrades in blood?
If a peptide is destroyed immediately in blood, it can't serve as a circulating signal or blood biomarker. This means dynorphin A works locally in tissues where it's released, while dynorphin B can travel through the bloodstream to affect distant organs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00494APA
Silberring, J; Li, Y M; Terenius, L; Nylander, I. (1998). Characterization of immunoreactive dynorphin B and beta-endorphin in human plasma.. Peptides, 19(8), 1329-37.
MLA
Silberring, J, et al. "Characterization of immunoreactive dynorphin B and beta-endorphin in human plasma.." Peptides, 1998.
RethinkPeptides
RethinkPeptides Research Database. "Characterization of immunoreactive dynorphin B and beta-endo..." RPEP-00494. Retrieved from https://rethinkpeptides.com/research/silberring-1998-characterization-of-immunoreactive-dynorphin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.